U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Hemoglobinopathies Market Growth & Trends
The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.
The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.
Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies’ strengths can accelerate drug development and improve treatment outcomes.
U.S. Hemoglobinopathies Market Report Highlights
U.S. Hemoglobinopathies Market Growth & Trends
The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.
The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.
Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies’ strengths can accelerate drug development and improve treatment outcomes.
U.S. Hemoglobinopathies Market Report Highlights
- Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.
- The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.
- The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.
- In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Diagnosis
1.2.3. Therapy
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Diagnosis outlook
2.2.3. Therapy outlook
2.3. Competitive Insights
CHAPTER 3. U.S. HEMOGLOBINOPATHIES MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Hemoglobinopathies Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. HEMOGLOBINOPATHIES MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Hemoglobinopathies Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Thalassemia
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Sickle cell disease
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Other Hb variants
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. U.S. HEMOGLOBINOPATHIES MARKET: DIAGNOSIS ESTIMATES & TREND ANALYSIS
5.1. Diagnosis Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Thalassemia
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Alpha
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.2. Blood test
5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.3. Genetic test
5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.4. Prenatal genetic test
5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.5. Pre-implantation genetic test
5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.6. Electrophoresis
5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.7. Others
5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Beta
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.2. Blood test
5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.3. Genetic test
5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.4. Prenatal genetic test
5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.5. Pre-implantation genetic test
5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.6. Electrophoresis
5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.7. Others
5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Sickle cell disease
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Blood test
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Genetic test
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.4. Prenatal genetic test
5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.5. Electrophoresis
5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.6. Others
5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hb variants
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.2. Blood test
5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.3. Genetic test
5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.4. Prenatal genetic test
5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.5. Electrophoresis
5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.6. Others
5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. U.S. HEMOGLOBINOPATHIES MARKET: THERAPY ESTIMATES & TREND ANALYSIS
6.1. Therapy Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Thalassemia
6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.2. Alpha
6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.2.2. Blood transfusion
6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.2.2. Iron chelation therapy
6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.3. Bone marrow transplant
6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.4. Others
6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3. Beta
6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.3.2. Blood transfusion
6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.2.2. Iron chelation therapy
6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.3. Bone marrow transplant
6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.4. Others
6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Sickle Cell Disease
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.2. Blood transfusion
6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.3. Hydroxyurea
6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.4. Bone marrow transplant
6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.5. Others
6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. (Hb) Variants
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.2. Blood transfusion
6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.3. Hydroxyurea
6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.4. Bone marrow transplant
6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.5. Others
6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
7.4.1. Sangamo Therapeutics, Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Global Blood Therapeutics, Inc.
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. bluebird bio, Inc.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Emmaus Life Sciences Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Pfizer, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Novartis AG
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Prolong Pharmaceuticals, LLC
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Bioverativ Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Celgene Corp.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Diagnosis
1.2.3. Therapy
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Diagnosis outlook
2.2.3. Therapy outlook
2.3. Competitive Insights
CHAPTER 3. U.S. HEMOGLOBINOPATHIES MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Hemoglobinopathies Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. HEMOGLOBINOPATHIES MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Hemoglobinopathies Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Thalassemia
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Sickle cell disease
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Other Hb variants
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. U.S. HEMOGLOBINOPATHIES MARKET: DIAGNOSIS ESTIMATES & TREND ANALYSIS
5.1. Diagnosis Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Thalassemia
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Alpha
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.2. Blood test
5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.3. Genetic test
5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.4. Prenatal genetic test
5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.5. Pre-implantation genetic test
5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.6. Electrophoresis
5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.7. Others
5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Beta
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.2. Blood test
5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.3. Genetic test
5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.4. Prenatal genetic test
5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.5. Pre-implantation genetic test
5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.6. Electrophoresis
5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.7. Others
5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Sickle cell disease
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Blood test
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Genetic test
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.4. Prenatal genetic test
5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.5. Electrophoresis
5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.6. Others
5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hb variants
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.2. Blood test
5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.3. Genetic test
5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.4. Prenatal genetic test
5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.5. Electrophoresis
5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.6. Others
5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. U.S. HEMOGLOBINOPATHIES MARKET: THERAPY ESTIMATES & TREND ANALYSIS
6.1. Therapy Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Thalassemia
6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.2. Alpha
6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.2.2. Blood transfusion
6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.2.2. Iron chelation therapy
6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.3. Bone marrow transplant
6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.4. Others
6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3. Beta
6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.3.2. Blood transfusion
6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.2.2. Iron chelation therapy
6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.3. Bone marrow transplant
6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.4. Others
6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Sickle Cell Disease
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.2. Blood transfusion
6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.3. Hydroxyurea
6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.4. Bone marrow transplant
6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.5. Others
6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. (Hb) Variants
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.2. Blood transfusion
6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.3. Hydroxyurea
6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.4. Bone marrow transplant
6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.5. Others
6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
7.4.1. Sangamo Therapeutics, Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Global Blood Therapeutics, Inc.
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. bluebird bio, Inc.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Emmaus Life Sciences Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Pfizer, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Novartis AG
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Prolong Pharmaceuticals, LLC
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Bioverativ Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Celgene Corp.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. hemoglobinopathies market: market outlook
Fig. 9 U.S. hemoglobinopathies competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. hemoglobinopathies market driver impact
Fig. 15 U.S. hemoglobinopathies market restraint impact
Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. hemoglobinopathies market: market outlook
Fig. 9 U.S. hemoglobinopathies competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. hemoglobinopathies market driver impact
Fig. 15 U.S. hemoglobinopathies market restraint impact
Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
